Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Indoleamine 2,3-dioxygenase Stories

2014-02-10 12:26:14

GOSSELIES, Belgium, February 10, 2014 /PRNewswire/ -- iTeos Therapeutics SA today announced the filing of the Company's first patent applications protecting proprietary inhibitors of the intracellular enzyme TDO2, which is expressed at high levels in specific cancers. iTeos Therapeutics has collaborated with Ludwig Cancer Research over the last year to identify small molecule inhibitors of the enzyme that display nanomolar potency, good selectivity, favorable pharmacokinetics...

2013-04-08 08:29:46

Results Support Further Evaluation of NLG919 for the treatment of Immunosupression Associated with Cancers AMES, Iowa, April 8, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic products in oncology, announced today that the company presented preclinical data for NLG919, a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, at the American...